Physostigmine

Physostigmine: Overview

Physostigmine is a tertiary amine alkaloid belonging to the reversible cholinesterase inhibitor class used as a central anticholinergic antidote. It is administered parenterally via intravenous or intramuscular injection under brand names like Antilirium to inhibit acetylcholinesterase, cross the blood-brain barrier, elevate synaptic acetylcholine, and reverse central anticholinergic toxicity, delirium, and elevated intraocular pressure.

What Is Physostigmine & How Does It Work?

Physostigmine is an alkaloid derived from the Calabar bean. Acetylcholine mediates parasympathetic, neuromuscular, and cognitive signals, while acetylcholinesterase hydrolyzes acetylcholine. Anticholinergic toxicity blocks muscarinic receptors, causing delirium, hallucinations, hyperthermia, and tachycardia.

Physostigmine works through acetylcholinesterase carbamylation, blood-brain barrier penetration, and indirect receptor stimulation. Following administration, Physostigmine crosses the blood-brain barrier into central nervous system tissue. At synapses, Physostigmine carbamylates acetylcholinesterase, preventing acetylcholine breakdown. Accumulating acetylcholine overcomes anticholinergic blockade at central and peripheral synapses. Restored cholinergic transmission reverses toxic delirium and coma, while ocular acetylcholine contracts the iris sphincter, lowering intraocular pressure.

Is Physostigmine FDA Approved?

Physostigmine salicylate was historically granted US FDA approval as a prescription injection under the brand name Antilirium in July 1976. However, this New Drug Application (NDA) was subsequently withdrawn. Today, physostigmine formulations are marketed in the United States as unapproved drugs.

What Is Physostigmine Used For?

• Reversal of severe central and peripheral anticholinergic toxicity caused by drug overdose or plant poisoning (FDA Approved).
• Treatment of anticholinergic-induced delirium, hallucinations, agitation, and coma in emergency toxicology (FDA Approved).
• Management of elevated intraocular pressure in chronic open-angle glaucoma (FDA Approved).
• Reversal of postoperative somnolence and delirium induced by scopolamine or atropine (Off-label use).
• Management of hereditary ataxia and Alzheimer disease cognitive impairment (Off-label use).
• Research evaluating acetylcholinesterase carbamylation kinetics and receptor modulation (Unapproved; research use).

Before Taking Physostigmine: Contraindications & Precautions

Evaluating cardiac conduction, airway reactivity, and mechanical obstruction is essential before administering Physostigmine.

Who Should Not Take Physostigmine?

Physostigmine is contraindicated in patients with severe hypersensitivity to Physostigmine, carbamates, or formulation bisulfites.

It is strictly contraindicated in mechanical gastrointestinal or urogenital obstruction, asthma, gangrene, diabetes, or cardiovascular disease. Physostigmine is also contraindicated in tricyclic antidepressant overdose with QRS prolongation over 100 milliseconds, as rapid cholinergic surges precipitate refractory ventricular arrhythmias and heart block.

Physostigmine: Pregnancy & Fertility

Animal reproduction studies demonstrate potential embryo-fetal toxicity at maternal toxic doses. Physostigmine crosses the placenta and can cause fetal cholinergic stimulation. Physostigmine should be administered during pregnancy only when potential clinical benefits justify potential fetal risks in life-threatening toxicity.

It is unknown whether systemic Physostigmine is excreted in human breast milk. Caution is advised when administering to nursing mothers. Fertility studies demonstrate no documented reproductive toxicity.

Tell Your Doctor Before Taking Physostigmine

Tell your physician if you have a history of asthma, chronic obstructive pulmonary disease, or cardiac arrhythmias. Disclose epilepsy, peptic ulcer disease, or intestinal obstruction.

Inform your doctor if you suspect toxic overdose from tricyclic antidepressants, antihistamines, or plants. Disclose concurrent medications, particularly depolarizing muscle relaxants, cholinergic agonists, and beta-blockers.

Physostigmine: Dosage & Administration

Proper administration and dosage depend on toxicological response, patient age, continuous cardiac monitoring, and emergency resuscitation readiness.

Standard Physostigmine Dosing

For adult severe anticholinergic toxicity, standard dosing is slow intravenous or intramuscular injection of 0.5 mg to 2 mg of Physostigmine salicylate at a rate not exceeding 1 mg per minute.

If symptoms persist, repeat doses of 1 mg to 4 mg may be administered every 20 to 30 minutes. For pediatric toxicity, standard dosing is slow intravenous injection of 0.02 mg/kg (up to 0.5 mg per dose) repeated every 5 to 10 minutes until response or a total dose of 2 mg is reached.

How Physostigmine Is Administered

Physostigmine is supplied as a sterile 1 mg/mL injection solution for intravenous or intramuscular administration by healthcare professionals.

Administer Physostigmine slowly over 2 to 5 minutes. Rapid bolus administration must be avoided, as rapid delivery precipitates bradycardia, bronchospasm, and seizures. Maintain continuous cardiac monitoring during injection and ensure atropine sulfate is available.

Physostigmine: Clinical Efficacy & Research

Clinical trials established that intravenous Physostigmine rapidly reverses central anticholinergic delirium, agitation, and coma within 5 to 20 minutes, demonstrating superiority over supportive care alone.

Research confirmed that the tertiary amine structure of Physostigmine permits rapid blood-brain barrier penetration, reversing central toxicity. Clinical studies confirmed that Physostigmine resolves delirium and restores clear sensorium in anticholinergic overdose.

Physostigmine: Side Effects & Safety Profile

Clinical use of Physostigmine requires monitoring for cholinergic toxicity, bradycardia, bronchospasm, and seizures.

Common Physostigmine Side Effects

• Gastrointestinal symptoms including nausea, vomiting, abdominal cramps, diarrhea, and profuse salivation.
• Autonomic symptoms including diaphoresis, lacrimation, bronchial hypersecretion, and urinary urgency.
• Neurological symptoms including restlessness, muscle twitching, tremor, dizziness, and mild headache.
• Ocular symptoms including miosis, blurred vision, ciliary spasm, and brow ache following exposure.

Serious Physostigmine Adverse Events

• Severe bradycardia, complete heart block, hypotension, and cardiac arrest secondary to vagal stimulation.
• Severe bronchospasm, laryngospasm, and pulmonary edema in susceptible patients.
• Generalized tonic-clonic seizures from rapid intravenous bolus injection.
• Refractory ventricular arrhythmias and asystole when administered in tricyclic antidepressant overdose with conduction delays.

Managing Physostigmine Side Effects

If mild nausea or diaphoresis occurs, slow the infusion rate and monitor vital signs.

If severe bradycardia, bronchospasm, seizures, or cardiac arrest develops, discontinue Physostigmine immediately, establish an airway, administer oxygen, and inject intravenous atropine sulfate (0.5 mg to 1 mg). Manage seizures with intravenous benzodiazepines.

Physostigmine: Interactions & What to Avoid

Physostigmine creates potential for drug interactions when combined with cholinergic modulators, cardiac medications, or muscle relaxants.

Physostigmine: Interactions

Co-administration of Physostigmine with depolarizing neuromuscular blockers like succinylcholine leads to prolonged respiratory paralysis due to plasma cholinesterase inhibition.

Co-administration with other cholinesterase inhibitors produces additive toxicity. Concomitant use with beta-blockers exacerbates bradycardia and AV block. Anticholinergic drugs such as atropine directly antagonize Physostigmine actions.

Physostigmine: Food & Alcohol

Parenteral administration of Physostigmine is not affected by oral food intake.

Alcohol consumption should be avoided following Physostigmine therapy. Alcohol can compound central nervous system depression and complicate neurological evaluation.

Physostigmine: Missed Dose, Overdose & Storage

Strict adherence to emergency protocols and proper hospital pharmacy storage maintains formulation potency and prevents toxicity.

Missed Dose of Physostigmine

Because Physostigmine is administered as an emergency antidote by healthcare professionals, routine daily missed doses do not apply.

If central anticholinergic toxicity recurs following initial reversal, the clinician will evaluate the patient and administer additional doses as indicated.

Physostigmine: Overdose & Emergency

Accidental overdose or rapid intravenous bolus of Physostigmine causes severe cholinergic poisoning, marked by bradycardia, bronchospasm, seizures, coma, and respiratory failure.

In case of overdose, discontinue Physostigmine immediately and initiate emergency resuscitation. Maintain airway and oxygenation, and inject intravenous atropine sulfate (0.5 mg to 1 mg) until toxicity resolves.

How to Store Physostigmine

Store Physostigmine salicylate injection vials at room temperature between 20 degrees Celsius and 25 degrees Celsius. Protect vials from light, heat, and freezing. Discard discolored or precipitated solutions.

Physostigmine: Patient Management & Monitoring

Systematic patient evaluation, continuous cardiac monitoring, and clinical surveillance optimize antidote safety and prevent toxicity recurrence.

Tests Before Starting Physostigmine

• Baseline 12-lead electrocardiogram to evaluate cardiac conduction, QRS width, and screen for tricyclic antidepressant toxicity.
• Baseline assessment of vital signs, pupil size, and neurological Glasgow Coma Scale score.
• Baseline arterial blood gas and electrolyte evaluation in toxic overdose settings.

Monitoring During Physostigmine Treatment

• Continuous cardiac rhythm, blood pressure, and pulse oximetry monitoring during and following administration.
• Continuous neurological observation for resolution of delirium or onset of toxicity.
• Monitoring for recurrent anticholinergic toxicity as Physostigmine is metabolized faster than offending agents.

Physostigmine: Do’s and Don’ts

• Do administer Physostigmine slowly over at least 2 minutes with continuous cardiac monitoring.
• Do keep intravenous atropine sulfate available at the bedside during injection.
• Don’t administer Physostigmine rapidly via intravenous bolus to prevent seizures and bradycardia.
• Don’t administer Physostigmine in tricyclic antidepressant overdose with QRS prolongation over 100 milliseconds.

Frequently Asked Questions

References

• Official FDA Prescribing Information and Approval History: Antilirium (Physostigmine Salicylate Injection), Application No. NDA 018021.
• DrugBank Online: Physostigmine (DB00981) Profile and Pharmacological Data.
• National Center for Biotechnology Information PubChem Compound Summary: Physostigmine.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or clinic before starting or stopping any medication.